Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation

DSA were inadequate to diagnose pAMR. Class II DSA provided prognostic information regarding future pAMR, graft dysfunction with pAMR, and graft loss.